Advertisement

Topics

FDA Approves Imbruvica (ibrutinib) for Chronic Graft Versus Host Disease

18:08 EDT 2 Aug 2017 | Drugs.com

August 2, 2017 -- The U.S. Food and Drug Administration today expanded the approval of Imbruvica (ibrutinib) for the treatment of adult patients with chronic graft versus host disease (cGVHD) after failure of one or more treatments. This is the...

Original Article: FDA Approves Imbruvica (ibrutinib) for Chronic Graft Versus Host Disease

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Imbruvica (ibrutinib) for Chronic Graft Versus Host Disease"

Quick Search
Advertisement